COMPARATIVE ANALYSIS OF THERAPY OUTCOMES IN PATIENTS WITH WEST SYNDROME RECEIVING TETRAСOSACTIDЕ AND OTHER ANTIEPILEPTIC DRUGS
https://doi.org/10.17650/2073-8803-2017-12-3-44-50
Abstract
Objective: a retrospective assessment of short-term and long-term results of combined therapy with the inclusion of tetracosactide in comparison with other antiepileptic drugs (AED) in West syndrome.
Materials and methods. The research covered 150 children with confirmed West syndrome treated at Pediatic Clinical Hospital No. 8 (Kazan, Russia) in 2000–2015. The age of children at the time of research was 4.0–14.5 years. The risk ratio (RR) and their confidence intervals (CIs) were calculated using RevMan 5.0 Software (http://community.cochrane.org). Differences for p <0.05 were considered valid.
Results and discussion. The children with West syndrome were divided into 2 groups: 1st group included 90 children who received tetracosactide in combination with other AED, 2nd group included 60 children who received any variants of AED excluding tetracosactide. Children in both groups were comparable in age, sex, neurological status and severity of their disease. After 2 weeks from the start of treatment, there were more patients with complete control of seizures in 1st group (who used tetracosactide) than in 2nd group (without tetracosactide): 68 of 90 (76 %) patients in 1st group, 1 of 60 (2 %) patients – in 2nd group, RR 45.33, 95 % CI 6.47–317.71, p = 0.0001. After 2 months and 6 months the results were the following: 69 of 90 (77 %) patients in 1st group, 13 of 60 (22 %) patients in 2nd group, RR 3.54, 95 % CI 2.16–5.80, p <0.00001; 69 of 90 (77 %) patients in 1st group, 36 of 60 (60 %) patients in 2nd group; RR 1.28, 95 % CI 1.01–1.62, p = 0.04 respectively. Long-term results of treatment (favorable outcome – complete clinical remission during 3 years or more) did not differ significantly in both groups: 59 of 90 (66 %) patients in 1st group and 37 of 60 (61,6 %) patients in 2nd group. For long-term outcomes RR 1.12, 95 % CI 0.88–1.42, p = 0.37.
Conclusions. The effectiveness of tetracosactide (favorable outcome – complete absence of seizures) with short-term observation (not less than 6 months) is higher in comparison with other AED in the absence of difference in safety. The long-term results of West syndrome treatment (with observation for 3 years or more) in children who received tetracosactide and in children who received other AED are comparable.
About the Authors
M. E. Farnosova
Kazan Federal University;
Children’s City Hospital No. 8
Russian Federation
Russian Federation
Department of Fundamental and Clinical Pharmacology, Institute of Fundamental Medicine and Biology, 18 Kremlevskaya St., Kazan 420000;
11 Bari Galeeva St., Kazan 420061
R. G. Gamirova
Kazan Federal University;
Children’s City Hospital No. 8
Kazan State Medical Academy, branch of the Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia;
Research Laboratory «Clinical Linguistics», Kazan Federal University
Russian Federation
Russian Federation
Department of Fundamental and Clinical Pharmacology, Institute of Fundamental Medicine and Biology, 18 Kremlevskaya St., Kazan 420000;
11 Bari Galeeva St., Kazan 420061;
Department of Pediatric Neurology, 11 Mushtari St., Kazan 420012;
18 Kremlevskaya St., Kazan 420000
References
1. Appleton R.E., Peters A.C., Mumford J.P. et al. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999;40(11):1627–33. PMID: 10565592.
2. Askalan R., Mackay M., Brian J. Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms. J Child Neurol 2003;18(3):165–70. DOI: 10.1177/08830738030180030801. PMID: 12731640.
3. Bobele G.B., Ward K.E., Bodensteiner J.B. Hypertrophic cardiomyopathy during corticotropin therapy for infantile spasm. A clinical and echocardiographic study. Am J Dis Child 1993;147(2):223–5. DOI: 10.1001/archpedi.1993.021602601133037. PMID: 8381257.
4. Cilio M.R., Kartashov A.I., Vigevano F. The long-term use of felbamate in children with severe refractory epilepsy. Epilepsy Res 2001;47:1–7. DOI: 10.1016/S0920-1211(01)00290-X. PMID: 11673015.
5. Hancock E.C., Osborne J.P., Edwards S.W. Treatment of infantile spasms. Cochrane Database Syst Rev 2013;5(6):CD001770. DOI: 1002/14651858.CD001770.pub3. PMID: 23740534.
6. Hrachovy R.A., Frost J.D. Infantile epileptic encephalopathy with hypsarrhythmia (infantile spasms/West syndrome). J Clin Neurophysiol 2003;20(6):408–25. PMID: 14734931.
7. Lawlor K.M., Devlin A.M. Levetiracetam in the treatment of infantile spasms. Eur J Paediatr Neurol 2005;9:e19–22. DOI: 10.1016/j.ejpn.2004.11.001. PMID: 15701562.
8. Lombroso C.T. A prospective study of infantile spasms: clinical and therapeutic correlations. Epilepsia 1983;24:135–58. DOI: 10.1111/j.1528-1157.1983. tb04874.x. PMID: 6299719.
9. Mackay M.T., Weiss S.K., Adams-Webber T. et al. Practice parameter: medical treatment of infantile spasms. Report of the Аmerican Academy of Neurology and the Child Neurology Society. Neurology 2004;62(10):1668–81. PMID: 15159460.
10. Mikati M.A., Fayad M., Koleilat M. et al. Efficacy, tolerability, and kinetics of lamotrigine in infants. J Pediatr 2002;141:31–5. DOI: 10.1067/ mpd.2002.125256. PMID: 12091848.
11. Pellock J.M., Hrachovy R., Shinnar S. Infantile spasms: a U.S. consensus report. Epilepsia 2010;51(10):2175–89. DOI: 10.1111/j.1528-1167.2010.02657.x. PMID: 20608959.
12. Peltzer B., Alonso W.D., Porter B.E. Topiramate and adrenocorticotropic hormone (ACTH) as initial treatment for infantile spasms. J Child Neurol 2009;24(4):400–5. DOI: 10.1177/0883073808324538. PMID: 19225138.
13. Rajaraman R.R., Lay J., Alayari A. et al. Prevention of infantile spasms relapse: Zonisamide and topiramate provide no benefit. Epilepsia 2016;57(8):1280–7. DOI: 10.1111/epi.13442. PMID: 27312124.
14. Riikonen R. Recent Advances in the Pharmacotherapy of Infantile Spasms. CNS Drugs 2014;28:279–90. DOI: 10.1007/ s40263-014-0139-5. PMID: 24504827.
15. Riikonen R., Simell O., Jaaskelainen J. et al. Disturbed calcium and phosphate homeostasis during treatment with ACTH of infantile spasms. Arch Dis Child 1986;61:671–6. DOI: 10.1136/ adc.61.7.671. PMID: 3017235.
16. Shamir R., Garty B.Z. Pneumocystis carinii pneumonia associated with adrenocorticotrophic hormone treatment for infantile spasms. Eur J Pediatr 1992;151(11):867. DOI: 10.1007/ BF01957945. PMID: 1468469.
17. Sorel L., Dusaucy-Bayloye H. A propos de 21 cas d‘hypsarythmie de Gibbs. Son Traitement spectaculaire par l’ACTH. Acta Neurol Psychiatr Belg 1958;58(2):130–41. PMID: 13532578.
18. Veggiotti P., Cieuta C., Rex E., Dulac O. Lamotrigine in infantile spasms. Lancet 1994;344:1375–6. DOI: 10.1016/S0140-6736(94)90741-2. PMID: 7968065.
19. Weber A., Cole J.W., Mytinger J.R. Infantile spasms respond poorly to topiramate. Pediatr Neurol 2015;53(2):130–4. DOI: 10.1016/j.pediatrneurol.2015.05.003.
20. Wheless J.W., Gibson P.A., Rosbeck K.L. Infantile spasms (West syndrome): update and resources for pediatricians and providers to share with parents. BMC Pediatr 2012;12:108. DOI: 10.1186/1471-2431-12-108. PMID: 22830456.
21. Wild J.M., Chiron C., Ahn H. et al. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study. CNS Drugs 2009;23(11):965– 82. DOI: 10.2165/11317650-000000000-00000. PMID: 19845417.
22. Wilmshurst J.M., Gaillard W.D., Vinayan K.P. et al. Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics. Epilepsia 2015;56(8):e1185–97. DOI: 10.1111/epi.13057. PMID: 26122601.
23. Yanai S., Hanai T., Narazaki O. Treatment of infantile spasms with zonisamide. Brain Dev 1999;21:157–61. DOI: 10.1016/s0387-7604(98)00080-1. PMID: 10372900.
24. Young R.S., Fripp R.R., Stern D.R., Darowish C. Cardiac hypertrophy associated with ACTH therapy for childhood seizure disorder. J Child Neurol 1987;2(4):311–2. DOI: 10.1177/088307388700200417. PMID: 2821097.
Review
For citations:
Farnosova M.E., Gamirova R.G. COMPARATIVE ANALYSIS OF THERAPY OUTCOMES IN PATIENTS WITH WEST SYNDROME RECEIVING TETRAСOSACTIDЕ AND OTHER ANTIEPILEPTIC DRUGS. Russian Journal of Child Neurology. 2017;12(3):44-50. (In Russ.) https://doi.org/10.17650/2073-8803-2017-12-3-44-50
Views:
908
Email this article 